// App-Quantinova.ai

POS0299 (2022) : EFFECT OF SECUKINUMAB ON RADIOGRAPHIC PROGRESSION AND INFLAMMATION IN SACROILIAC JOINTS AND SPINE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR IMAGING OUTCOMES FROM A PHASE III RANDOMISED TRIAL

Researchers

Presenter

  • J. Braun

Principal Investigators

  • R. Blanco

  • H. Marzo-Ortega

  • L. S. Gensler

  • F. Van den Bosch

  • S. Hall

  • H. Kameda

  • D. Poddubnyy

  • M. G. H. Van de Sande

  • D. Van der Heijde

  • T. Zhuang

  • A. Stefanska

  • A. Readie

  • H. Richards

  • A. Deodhar

Medical Centers

  • Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Department of Rheumatology, Bochum, Germany

  • Hospital Universitario Marqués de Valdecilla. IDIVAL., Rheumatology and Ophthalmology, Santander, Spain

  • NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom

  • University of California, Department of Rheumatology, San Francisco, CA, United States of America

  • Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, VIB Center for Inflammation Research, Ghent, Belgium

  • Monash University, Department of Medicine, Alfred Campus, Melbourne, Australia

  • Toho University, Division of Rheumatology, Tokyo, Japan

  • Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany

  • Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Rheumatology and immunology Center and Epidemiology and Biostatics, Amsterdam, Netherlands

  • Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands

  • Novartis Pharmaceuticals Corporation, Rheumatology, New Jersey, United States of America

  • Novartis Ireland Limited, Rheumatology, Dublin, Ireland

  • Novartis Pharma AG, Rheumatology, Basel, Switzerland

  • Oregon Health and Science University, Rheumatology Clinica Division of Arthritis and Rheumatic Diseases, Portland, United States of America

Locations

  • Germany

  • Spain

  • United Kingdom

  • United States

  • Belgium

  • Australia

  • Japan

  • Netherlands

  • Ireland

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Non-radiographic axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT02696031

Sponsors

  • AbbVie Inc

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved